EPHA4 Regulates the Transition between Mesenchymal and Hybrid States in TNBC
- 1University of Chicago
Abstract
Metastatic progression in triple-negative breast cancer (TNBC) is strongly influenced by epithelial-mesenchymal plasticity (EMP), which enables transitions between epithelial, hybrid epithelial/mesenchymal (E/M), and mesenchymal cell states. While mesenchymal cells are highly invasive and resistant to therapy, hybrid E/M states confer advantages during metastatic colonization. Both mesenchymal and hybrid states therefore contribute to tumor aggressiveness through distinct mechanisms. However, the molecular regulation governing transitions between mesenchymal and hybrid E/M states remains poorly understood. Here, we identify EPHA4 as a regulator of this transition in TNBC. EPHA4 expression is enriched in mesenchymal TNBC cells, and genetic knockout of EPHA4 in MDA-MB-231 xenograft and 4T1 syngeneic models induces a shift toward hybrid E/M phenotypes. This transition reduces cellular invasion while enhancing metastatic colonization, consistent with the clinical observations of decreased EPHA4 expression in secondary metastases compared to primary tumors. Despite compensatory changes in other Eph/ephrin family members following EPHA4 loss, EPHA4 deficiency is sufficient to drive this phenotypic shift. These findings identify EPHA4 as a regulator of cancer cell plasticity in TNBC and highlight the therapeutic complexity of targeting pathways that govern metastatic state transitions.
Related
- From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions
- The atypical cadherin CELSR2 regulates distinct epithelial-mesenchymal states and oxidative phosphorylation in triple-negative breast cancer
- Curcumin carried by polystyrene nanoparticles inhibits phosphatidylinositol 3-kinase/protein kinase B signaling pathway through miR-186 and down-regulates Twist to inhibit the epithelial-mesenchymal transition in colorectal cancer in mice
- Isoliquiritigenin inhibits TGF-β1-induced epithelial–mesenchymal transition in pulmonary fibrosis by promoting Nix-mediated mitophagy
- UCHL1 Promotes Epithelial–Mesenchymal Transition Through E-Cadherin and N-Cadherin Switch in Endometrial Cancer
BibTeX
@misc{liu2026epha4,
title = {{EPHA4 Regulates the Transition between Mesenchymal and Hybrid States in TNBC}},
author = {W. Liu and H. W. Lee and M. H. Bungert and L. C. Nguyen and A. Kurowska and T. J. Lee and G. P. Yerradoddi and E. Suarez and M. R. Rosner},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.04.756472},
url = {https://www.biorxiv.org/content/10.64898/2026.10.04.756472v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - EPHA4 Regulates the Transition between Mesenchymal and Hybrid States in TNBC
AU - W. Liu
AU - H. W. Lee
AU - M. H. Bungert
AU - L. C. Nguyen
AU - A. Kurowska
AU - T. J. Lee
AU - G. P. Yerradoddi
AU - E. Suarez
AU - M. R. Rosner
PY - 2026
DA - 2026/10/04
PB - bioRxiv
DO - 10.64898/2026.10.04.756472
UR - https://www.biorxiv.org/content/10.64898/2026.10.04.756472v1
AB - Metastatic progression in triple-negative breast cancer (TNBC) is strongly influenced by epithelial-mesenchymal plasticity (EMP), which enables transitions between epithelial, hybrid epithelial/mesenchymal (E/M), and mesenchymal cell states. While mesenchymal cells are highly invasive and resistant to therapy, hybrid E/M states confer advantages during metastatic colonization. Both mesenchymal and hybrid states therefore contribute to tumor aggressiveness through distinct mechanisms. However, the molecular regulation governing transitions between mesenchymal and hybrid E/M states remains poorly understood. Here, we identify EPHA4 as a regulator of this transition in TNBC. EPHA4 expression is enriched in mesenchymal TNBC cells, and genetic knockout of EPHA4 in MDA-MB-231 xenograft and 4T1 syngeneic models induces a shift toward hybrid E/M phenotypes. This transition reduces cellular invasion while enhancing metastatic colonization, consistent with the clinical observations of decreased EPHA4 expression in secondary metastases compared to primary tumors. Despite compensatory changes in other Eph/ephrin family members following EPHA4 loss, EPHA4 deficiency is sufficient to drive this phenotypic shift. These findings identify EPHA4 as a regulator of cancer cell plasticity in TNBC and highlight the therapeutic complexity of targeting pathways that govern metastatic state transitions.
ER -